Trial Profile
A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab Compared With Chemotherapy in Patients With Treatment Naïve Advanced or Recurrent (Stage IIIb Not Amenable for Multimodality Treatment) or Metastatic (Stage IV) Non-Small Cell Lung Cancer Who Are Deemed Unsuitable for Platinum-Containing Therapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Gemcitabine; Vinorelbine; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms IPSOS
- Sponsors Roche
- 01 Nov 2023 Status changed from active, no longer recruiting to completed.
- 29 Sep 2023 Planned End Date changed from 15 Sep 2023 to 16 Oct 2023.
- 10 Aug 2023 Planned End Date changed from 1 Jul 2023 to 15 Sep 2023.